A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Shares of GSK PLC GSK inched down 0.48% to £13.34 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.12% to 8,311.76.

With that in mind, GSK is partnering with developer Reef and investor UBS Asset Management to build a 1.4M SF, £900M life ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

The data include an interim look at the dose-escalation portion of a phase 2 trial assessing the adenosine A2A receptor ...

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

GST registration in Haryana, Manipur, Meghalaya, and Tripura will now involve biometric Aadhaar authentication and document ...

A fiver a day seems like a small price to pay for a potentially lucrative second income later in life. But patience and ...

In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...

Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three ...

Me, a major company providing direct-to-consumer genetic testing, has been struggling financially since late 2023. In ...